DADC
JUNO

D.A. Davidson & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

D.A. Davidson & Co’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14,218
Closed -$650K – 1178
2017
Q4 		$650K Sell
14,218
-196,155
-93% -$9.78M 0.01% 581
2017
Q3 		$9.44M Sell
210,373
-8,645
-4% -$295K 0.19% 125
2017
Q2 		$6.55M Buy
219,018
+514
+0.2% +$12.7K 0.15% 127
2017
Q1 		$4.85M Buy
218,504
+2,453
+1% +$52.6K 0.12% 151
2016
Q4 		$4.07M Buy
216,051
+199,133
+1,177% +$4.87M 0.09% 211
2016
Q3 		$507K Buy
16,918
+4,900
+41% +$152K 0.01% 628
2016
Q2 		$461K Buy
12,018
+983
+9% +$40.8K 0.01% 566
2016
Q1 		$420K Sell
11,035
-385
-3% -$13.4K 0.01% 581
2015
Q4 		$502K Sell
11,420
-7,560
-40% -$375K 0.02% 541
2015
Q3 		$772K Buy
18,980
+2,125
+13% +$93.2K 0.03% 435
2015
Q2 		$898K Buy
16,855
+16,000
+1,871% +$849K 0.03% 428
2015
Q1 		$51K Buy
855
+305
+55% +$14.8K ﹤0.01% 1424
2014
Q4 		$28K Buy
+550
New +$24.6K ﹤0.01% 1602

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

D.A. Davidson & Co's JUNO Position: Q1 2018 in Review

D.A. Davidson & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 14,218 shares — an estimated $650K sold.

D.A. Davidson & Co first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $9.44M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • D.A. Davidson & Co reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 14,218 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $650K.
  • D.A. Davidson & Co first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • D.A. Davidson & Co's Juno Therapeutics, Inc. position peaked at $9.44M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on D.A. Davidson & Co's 13F filing for Q1 2018, filed 4 May 2018.